Invention Grant
![Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase](/docs/US/2020-07-07/US10702591B2/abs.jpg.600x600.jpg)
- Patent Title: Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase
-
Application No.: US15666947Application Date: 2017-08-02
-
Publication No.: US10702591B2Publication Date: 2020-07-07
- Inventor: Biswajit Biswas , Carl R. Merril , Hossein Ghanbari
- Applicant: Panacea Pharmaceuticals, Inc.
- Applicant Address: US MD Gaithersburg
- Assignee: Panacea Pharmaceuticals, Inc.
- Current Assignee: Panacea Pharmaceuticals, Inc.
- Current Assignee Address: US MD Gaithersburg
- Agency: Cooley LLP
- Agent Ivor Elrifi
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K14/47 ; C12N9/02
![Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase](/abs-image/US/2020/07/07/US10702591B2/abs.jpg.150x150.jpg)
Abstract:
The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
Public/Granted literature
- US20180092969A1 Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-Beta-Hydroxylase Public/Granted day:2018-04-05
Information query
